Does the Multiple Sclerosis Impact Scale-29 (MSIS-29) have the range to capture the experience of fully ambulatory multiple sclerosis patients? Learnings from the ASCLEPIOS studies.

Regnault, Antoine; Loubert, Angely; Brennan, Róisín; Meunier, Juliette; Naujoks, Christel; Cano, Stefan; Adlard, Nicholas

Regnault, Antoine; Loubert, Angely; Brennan, Róisín; Meunier, Juliette; Naujoks, Christel; Cano, Stefan; Adlard, Nicholas.

Afiliação

Regnault A; Modus Outcomes, Lyon, France.
Loubert A; Modus Outcomes, Lyon, France.
Brennan R; Novartis Pharma AG, Basel, Switzerland.
Meunier J; Modus Outcomes, Lyon, France.
Naujoks C; Novartis Pharma AG, Basel, Switzerland.
Cano S; Modus Outcomes, Letchworth Garden City, UK.
Adlard N; Novartis Pharma AG, Basel, Switzerland.

Mult Scler J Exp Transl Clin ; 9(3): 20552173231201422, 2023.

Article em En | MEDLINE | ID: mdl-37780483

Palavras-chave

Disability; Multiple Sclerosis Impact Scale-29; Rasch measurement theory; disease-modifying therapy; multiple sclerosis; patient-reported outcomes; physical impact; psychological impact; psychometric analysis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article